ATE503491T1 - Verbesserte anthraximpfstoffe und abgabeverfahren - Google Patents

Verbesserte anthraximpfstoffe und abgabeverfahren

Info

Publication number
ATE503491T1
ATE503491T1 AT03815990T AT03815990T ATE503491T1 AT E503491 T1 ATE503491 T1 AT E503491T1 AT 03815990 T AT03815990 T AT 03815990T AT 03815990 T AT03815990 T AT 03815990T AT E503491 T1 ATE503491 T1 AT E503491T1
Authority
AT
Austria
Prior art keywords
delivery methods
anthrax vaccines
vaccines
improved
improved anthrax
Prior art date
Application number
AT03815990T
Other languages
English (en)
Inventor
John Mikszta
Vincent Sullivan
Original Assignee
Becton Dickinson Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Becton Dickinson Co filed Critical Becton Dickinson Co
Application granted granted Critical
Publication of ATE503491T1 publication Critical patent/ATE503491T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/07—Bacillus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Otolaryngology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Polymers With Sulfur, Phosphorus Or Metals In The Main Chain (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT03815990T 2003-02-13 2003-08-13 Verbesserte anthraximpfstoffe und abgabeverfahren ATE503491T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US44699503P 2003-02-13 2003-02-13
US48646003P 2003-07-14 2003-07-14
PCT/US2003/025158 WO2004073735A1 (en) 2003-02-13 2003-08-13 Improved anthrax vaccines and delivery methods

Publications (1)

Publication Number Publication Date
ATE503491T1 true ATE503491T1 (de) 2011-04-15

Family

ID=32912248

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03815990T ATE503491T1 (de) 2003-02-13 2003-08-13 Verbesserte anthraximpfstoffe und abgabeverfahren

Country Status (7)

Country Link
US (1) US20070154494A1 (de)
EP (1) EP1592443B1 (de)
JP (1) JP2006517913A (de)
AT (1) ATE503491T1 (de)
AU (1) AU2003255275A1 (de)
DE (1) DE60336588D1 (de)
WO (1) WO2004073735A1 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8409590B2 (en) 2004-02-11 2013-04-02 Ligocyte Pharmaceuticals, Inc. Anthrax antigens and methods of use
GB0607462D0 (en) 2006-04-13 2006-05-24 Avecia Ltd Assay
US20080226729A1 (en) * 2006-09-08 2008-09-18 Becton, Dickinson And Company Stable powder formulations of alum-adsorbed vaccines
EP1972347A1 (de) * 2007-03-19 2008-09-24 Becton, Dickinson and Company, Wagner, Jaconda Stabile Impfstoffpulverformulierungen
KR20100045413A (ko) * 2007-06-14 2010-05-03 크루셀 스위츨랜드 아게 피내 인플루엔자 백신
CN101959527B (zh) 2008-03-05 2016-04-20 赛诺菲巴斯德有限公司 一种使含佐剂的疫苗组合物稳定的方法
AU2009299615B2 (en) 2008-10-02 2015-07-16 Pharmathene Inc. Anthrax vaccine formulation and uses thereof
WO2010084298A1 (en) * 2009-01-22 2010-07-29 Pharmathene Uk Limited Stable vaccine compositions and methods of use
US20100183675A1 (en) * 2009-01-22 2010-07-22 Allan Watkinson Stable vaccine compositions and methods of use
GB201007207D0 (en) * 2010-04-29 2010-06-16 Univ Cork Method
WO2013139384A1 (en) * 2012-03-21 2013-09-26 Dorkoosh, Farid Abedin Freezing of aerosolized solutions (fas): a system for continuous particle production
CN110227152A (zh) * 2012-04-23 2019-09-13 巴拉特生物技术国际有限公司 轮状病毒疫苗组合物及其制备方法
JP6028063B2 (ja) * 2015-04-30 2016-11-16 ナノメド ディヴァイシーズ， インコーポレイテッド アプリケータに統合可能な内蔵非言語的指示デバイス
KR102333037B1 (ko) * 2017-08-17 2021-12-01 코스메드 파마소티컬 씨오 쩜 엘티디 입술용 마이크로니들 어레이

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL7012832A (de) * 1970-08-29 1972-03-02
US5840312A (en) * 1991-05-02 1998-11-24 Institut Pasteur Recombinant Bacillus anthracis strains unable to produce the lethal factor protein or edema factor protein
JP2930526B2 (ja) * 1994-05-31 1999-08-03 株式会社キートロン インジェクター型アトマイザー
US6316006B1 (en) * 1994-11-23 2001-11-13 The United States Of America As Represented By The Secretary Of The Army Asporogenic B anthracis expression system
US6348450B1 (en) * 1997-08-13 2002-02-19 The Uab Research Foundation Noninvasive genetic immunization, expression products therefrom and uses thereof
US6284282B1 (en) * 1998-04-29 2001-09-04 Genentech, Inc. Method of spray freeze drying proteins for pharmaceutical administration
US6770479B1 (en) * 1998-07-10 2004-08-03 The United States Of America As Represented By The Secretary Of The Army Anthrax vaccine
US6329156B1 (en) * 1999-03-22 2001-12-11 The Regents Of The University Of California Method for screening inhibitors of the toxicity of Bacillus anthracis
FR2798291B1 (fr) * 1999-09-10 2005-01-14 Pasteur Institut Compositions acellulaires immunogenes et compositions acellulaires vaccinales contre bacillus anthracis
US6835184B1 (en) * 1999-09-24 2004-12-28 Becton, Dickinson And Company Method and device for abrading skin
US6595947B1 (en) * 2000-05-22 2003-07-22 Becton, Dickinson And Company Topical delivery of vaccines
WO2002100340A2 (en) * 2001-06-08 2002-12-19 Avant Immunotherapeutics, Inc. Improved vaccination against anthrax
CN1253220C (zh) * 2001-06-29 2006-04-26 贝克顿迪肯森公司 通过微管在真皮内输入疫苗和基因治疗剂
AU2002346424A1 (en) * 2001-11-19 2003-06-10 Becton, Dickinson And Company Pharmaceutical compositions in particulate form

Also Published As

Publication number Publication date
EP1592443A4 (de) 2007-02-21
WO2004073735A1 (en) 2004-09-02
AU2003255275A1 (en) 2004-09-09
JP2006517913A (ja) 2006-08-03
EP1592443A1 (de) 2005-11-09
DE60336588D1 (de) 2011-05-12
US20070154494A1 (en) 2007-07-05
EP1592443B1 (de) 2011-03-30

Similar Documents

Publication Publication Date Title
AR125327A2 (es) Composiciones de neisseria meningitidis y métodos de las mismas
ATE503491T1 (de) Verbesserte anthraximpfstoffe und abgabeverfahren
WO2007024941A3 (en) Polyvalent vaccine
NO2017005I1 (no) Human pappilomavirus vaksine [type 6, 11, 16, 18, 31, 33, 45, 52, 58]
PH12013502192A1 (en) Antibodies against human angiopoietin 2
IL223141A0 (en) Immunogenic composition for use in vaccination against staphylococcei
MX375202B (es) Composiciones adyuvantes novedosas.
WO2007054283A3 (en) Pqs and its conjugates as adjuvants and their uses in pharmaceutical compositions
UA99659C2 (uk) Мультивалентна вакцина з нативних везикул зовнішньої мембрани менінгококів, способи її застосування
TW200637522A (en) Skin treatment articles and methods
IL186458A0 (en) Skin enrichment using coq10 as the delivery system
IN2012DN02736A (de)
MX2007010996A (es) Nuevas composiciones de liposomas.
TW200740458A (en) Vaccination against dengue virus infection
CR9246A (es) Formulaciones terapeuticas del factor de crecimiento de queratinocitos
GB2386072A (en) Novel vaccine
MY149705A (en) Pyridino-pyridinone derivatives, preparation therof, and therapeutic use thereof
EP1708749A4 (de) Bakterielle flagelline als wirkkomponente enthaltende vakzineadjuvantien zur mukosalen anwendung
IL188176A0 (en) Stable pharmaceutical composition comprising linezolid form iv
WO2010053610A3 (en) Stable anthrax vaccine formulations
MX2009004866A (es) Vacuna para enfermedad de lyme canina.
WO2007059931A8 (en) New adjuvants on the basis of bisacyloxypropylcysteine conjugates and derivatives and their uses in pharmaceutical compositions
GB2444676A (en) Adjuvanted vaccine
DE602004006026D1 (de) Streptococcus-phocae-vakzine
WO2007028985A3 (en) Adjuvanted vaccine

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties